Platelet-Rich and Platelet-Poor Plasma Treatment Pre- and Post-Breeding 2 Differentially Regulates Gene Expression in Early Equine Embryos from Mares 3 Susceptible to Persistent Breeding-Induced Endometritis

For a mare, the journey to motherhood is a delicate negotiation between her own body and the tiny, developing life she carries. When a mare becomes pregnant, her uterus must shift from a state of readiness to a state of support, providing the perfect environment for an embryo to grow. However, in many mares, this transition is disrupted by a condition called persistent breeding-induced endometritis. In simple terms, this is an inflammation of the uterine lining that fails to clear up after breeding. Instead of settling down, the uterus remains in a state of chronic irritation, creating a hostile environment that can prevent an embryo from surviving or developing properly. This issue is a leading cause of infertility in the horse industry, leaving breeders with mares that repeatedly fail to carry a foal to term.

To combat this, veterinarians have turned to treatments derived from the mare's own blood. Two such treatments are platelet-rich plasma and platelet-poor plasma. Both are liquids separated from blood, but they differ in their concentration of platelets, the tiny cells best known for helping blood clot. Platelet-rich plasma is packed with these cells, while platelet-poor plasma has very few. For years, the prevailing belief was that the high concentration of platelets was the key to the treatment's success, as platelets release growth factors that help heal tissue and calm inflammation. Researchers assumed that the more platelets, the better the outcome. But a new study from the University of Illinois and the University of California, Davis, challenges this long-held assumption by looking not just at the mare, but at the very first words the embryo speaks.

The researchers set out to see if these blood treatments actually changed the genetic instructions inside the embryo itself. They worked with twelve mares known to be susceptible to the persistent inflammation that hinders pregnancy. In a carefully controlled experiment, these mares were treated with one of three fluids during their heat cycle: platelet-rich plasma, platelet-poor plasma, or a standard saltwater solution as a control. The treatments were given four times—twice before breeding and twice after—to ensure the uterine environment was modulated at the critical moment of conception. Eight days after the embryos formed, the team gently flushed the uterus to retrieve them. They then extracted the genetic material, or RNA, from each embryo to read which genes were turned on or off. This process, known as RNA sequencing, acts like a snapshot of the embryo's current state, revealing how it is responding to its surroundings.

The results were surprising. When the scientists compared the genetic profiles of the embryos, they found that the treatments had a massive impact. Embryos from mares treated with either type of plasma showed thousands of changes in gene expression compared to the untreated controls. More than 1,400 genes were altered in the platelet-poor group, and over 1,500 were changed in the platelet-rich group. The most striking discovery, however, was how similar the two treatments were. Despite the vast difference in platelet counts, the embryos from both groups reacted in almost the same way. About 76 percent of the genes changed by the platelet-poor treatment were also changed by the platelet-rich treatment. There were no genes that went in opposite directions; the treatments did not cancel each other out, nor did they produce completely different results. They spoke the same genetic language.

When the researchers looked closer at what these genes were actually doing, they found subtle but distinct differences. The embryos from the platelet-rich group showed increased activity in genes related to keeping cells stable and maintaining the integrity of the uterine lining. In contrast, the embryos from the platelet-poor group showed more activity in genes related to development and energy metabolism. Yet, these differences were matters of degree rather than kind. The overall pattern suggested that both treatments were guiding the embryo toward a similar, healthier state, just through slightly different pathways. The study indicates that the success of these therapies does not rely solely on the number of platelets present. Instead, the liquid part of the blood, which contains hundreds of other proteins and signaling molecules, appears to play an equally vital role in calming the uterus and helping the embryo thrive.

This finding shifts the understanding of how these treatments work. The researchers propose that the plasma is not acting directly on the embryo like a drug hitting a target. Instead, the treatment likely soothes the inflamed uterine lining, changing the chemical soup that the embryo swims through as it develops. By improving the maternal environment, the treatment indirectly influences the embryo's genetic programming. While the study does not yet prove that these genetic changes lead to more foals being born, it provides strong molecular evidence that the uterine environment can be fixed to support early life. It suggests that the simpler, less expensive platelet-poor plasma might be just as effective as the more complex platelet-rich version, opening the door to more accessible treatments for mares struggling with infertility. The work confirms that healing the mother is the first step to saving the child, and that the solution may lie in the quiet, complex chemistry of the blood itself.